indacaterol and glycopyrronium (QVA149)

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

COPDChronic Obstructive Pulmonary Disease (COPD)

Phase 3

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01202188

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2010-09-30End: 2012-03-31Updated: 2013-09-09

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01315249

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2011-03-31End: 2012-03-31Updated: 2013-08-09

Phase 4

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

CompletedNCT02566031

Novartis PharmaceuticalsCOPD

Start: 2013-03-23End: 2018-06-04Updated: 2019-09-23

Related Papers

Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.

2017-02-223 citations

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies

Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2014-01-018 citations

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

2012-12-06224 citations